Cargando…
A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment
Ibrutinib (IBR) covalently binds to the active site of Bruton’s tyrosine kinase (BTK) and is used for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). Approximately 5-10% of CLL is complicated by autoimmune cytopenia (AIC), such as autoimmune hemolytic anemia (AIHA). Several...
Autores principales: | Suzuki, Takaharu, Miyakoshi, Shukuko, Nanba, Ayako, Uchiyama, Takayoshi, Kawamoto, Keisuke, Aoki, Sadao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JSLRT
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408179/ https://www.ncbi.nlm.nih.gov/pubmed/30012921 http://dx.doi.org/10.3960/jslrt.18012 |
Ejemplares similares
-
Autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia
por: Al Hadidi, Samer, et al.
Publicado: (2020) -
Measurable residual disease in the treatment of chronic lymphocytic leukemia
por: Uchiyama, Takayoshi, et al.
Publicado: (2020) -
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia: A Comprehensive Review
por: Autore, Francesco, et al.
Publicado: (2021) -
Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia
por: Hamamyh, Tahseen, et al.
Publicado: (2020) -
Etiopathogenesis and prognostic implications of autoimmune hemolytic anemia association with chronic lymphocytic leukemia B
por: Oprea, MM, et al.
Publicado: (2012)